CSPC Innovative Pharmaceuticals Co., Ltd., a subsidiary of CSPC Pharmaceutical Group, is located at No. 62 Zhangju Road, Luancheng District, Shijiazhuang City. Founded in 1989, the company was restructured into a joint-stock enterprise in 2006 and listed on the Shenzhen Stock Exchange in 2019. It covers a total area of 112,000 square meters, with a registered capital of 1.171 billion yuan and a current workforce of over 1,800 employees.

The company is mainly engaged in the production, sales and R&D of xanthine series drugs. It is a designated manufacturer of national psychotropic drugs, a high-tech enterprise in Hebei Province, and the world's largest production base for chemically synthesized xanthine series products. Its main products include caffeine, theobromine, theophylline, aminophylline, diprophylline and pentoxifylline.

The company's products have obtained multiple quality system certifications including the new national GMP certification, US FDA certification, EU EDQM certification, Japan PMDA certification and UK BRC certification, winning wide recognition from customers at home and abroad. The products are exported to Europe, America, Japan, Australia, Southeast Asia and other countries and regions.

As a leading enterprise in the industry and a Manufacturing Single Champion Enterprise of Hebei Province, the company is also one of China’s earliest manufacturers engaged in the R&D and production of caffeine and theobromine; its products theobromine and pentoxifylline are exclusively manufactured domestically.The company’s core product, caffeine, is classified as a Category II psychotropic drug in China and subject to stringent national regulations. Meanwhile, as a food additive, caffeine is widely applied in functional beverage production. 

The company serves as a global supplier to internationally renowned enterprises including PepsiCo, Coca-Cola, Red Bull, 7 Up and GSK. For three consecutive years, it has ranked first nationwide in caffeine export volume, with a market share exceeding 60%, earning an outstanding reputation in the industry.The company boasts a well-structured, multi-disciplinary and experienced R&D team. Its R&D platform has been accredited as the Hebei Provincial Engineering Laboratory of Xanthine and Its Derivatives and the Hebei Provincial Enterprise Technology Center. 

The company’s new high-selective catalytic reduction process for dimethylalloxazine and new production process for theobromine have been recognized by the Hebei Provincial Department of Science and Technology as reaching the domestic leading level, and won the Hebei Provincial Science and Technology Achievement Award. Through continuous R&D efforts, the company has so far obtained 7 national invention patents and 4 utility model patents. Over the past five years, it has also been honored with 2 Third-Class Awards for Hebei Provincial Science and Technology Progress, 2 Hebei Provincial Science and Technology Achievements and 1 Hebei Provincial Excellent Patent Award.